Trials / Completed

CompletedNCT02182128

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 24 (actual)

Sponsor: Boehringer Ingelheim · Industry
Sex: All
Age: 20 Years
Healthy volunteers: Not accepted

Summary

Confirmation of BIBF 1120 administered from 150 mg twice daily (b.i.d.) to 250 mg b.i.d. as safe and tolerable treatment in Japanese patients with advanced solid tumours, overall safety, pharmacokinetic parameters, biomarkers, and efficacy of BIBF 1120.

Conditions

Tumors

Interventions

Type	Name	Description
DRUG	BIBF 1120

Timeline

Start date: 2006-06-01
Primary completion: 2009-06-01
First posted: 2014-07-08
Last updated: 2014-07-18

Source: ClinicalTrials.gov record NCT02182128. Inclusion in this directory is not an endorsement.